Top 10 Companies in the Frozen Animal Blood Plasma Market (2026): Market Leaders Powering Global Biopharmaceuticals

MARKET INSIGHTS

Global frozen animal blood plasma market size was valued at USD 1370 million in 2024 and is projected to reach USD 1961 million by 2032, growing at a CAGR of 5.3% during the forecast period.

Frozen animal blood plasma refers to processed blood components derived from healthy livestock (primarily bovine and porcine sources), preserved through cryogenic storage at temperatures below -20°C. This biological material contains essential proteins like albumin and immunoglobulins, along with bioactive compounds, making it valuable across pharmaceutical, nutritional, and cosmetic applications. The frozen preservation method ensures extended shelf life while maintaining functional integrity.

The market expansion is driven by increasing pharmaceutical applications in plasma‑derived therapeutics and vaccine production, which accounted for 42% of total consumption in 2024. However, supply chain volatility in raw material procurement presents a key challenge, with seasonal fluctuations causing 15‑20% price variations annually. Recent technological advancements in plasma fractionation and cold‑chain logistics are addressing these limitations, with companies like Grifols and CSL investing over USD 120 million collectively in production facility upgrades during 2023‑2024.

Frozen Animal Blood Plasma Market – View in Detailed Research Report

Top 10 Companies in the Frozen Animal Blood Plasma Market (2026)

---

🔟 1. CSL Limited

Headquarters: Melbourne, Australia
Key Offering: Bovine and porcine plasma collection, fractionation, and distribution

CSL has built a vertically integrated network that spans plasma collection sites, processing facilities, and end‑user distribution. The company’s proprietary pathogen‑reduction technology ensures product safety, while its extensive logistics infrastructure supports a steady supply chain across multiple continents.

Sustainability & Growth Initiatives:

• Investment in cryogenic storage upgrades to reduce energy consumption
• Partnerships with livestock producers to secure disease‑free herds
• Expansion of contract manufacturing agreements with biopharmaceutical clients

---

9️⃣ 2. Grifols S.A.

Headquarters: Barcelona, Spain
Key Offering: Plasma fractionation, immunoglobulin products, and vaccine raw materials

Grifols leverages its long‑standing expertise in plasma processing to supply high‑purity proteins for therapeutic use. The firm’s recent investment in modular processing units has cut operating costs by 30%, enabling it to serve mid‑sized biopharma firms more competitively.

Sustainability & Growth Initiatives:

• Implementation of blockchain traceability for raw material sourcing
• Development of eco‑friendly cryopreservation protocols
• Strategic alliances with vaccine manufacturers to secure long‑term contracts

---

8️⃣ 3. Biovet

Headquarters: Lyon, France
Key Offering: Plasma‑derived therapeutic proteins and animal nutrition products

Biovet’s dual focus on medical and industrial applications positions it well to capture demand from both pharmaceutical and feed‑supplement markets. Its robust quality‑assurance framework aligns with stringent EU regulations, ensuring smooth market entry for new product lines.

Sustainability & Growth Initiatives:

• Investment in high‑efficiency centrifugation technology
• Expansion of plant‑based protein research to diversify product portfolio
• Collaboration with academic institutions for next‑generation plasma therapeutics

---

7️⃣ 4. Vetoquinol

Headquarters: Paris, France
Key Offering: Swine plasma derivatives for veterinary therapeutics and feed additives

Vetoquinol’s niche focus on species‑specific plasma products has earned it a strong foothold in the European veterinary market. The company’s recent launch of a new bovine serum albumin line for cell‑culture media demonstrates its commitment to high‑value applications.

Sustainability & Growth Initiatives:

• Integration of waste‑reduction protocols in plasma processing
• Partnerships with regional slaughterhouses to secure disease‑free plasma
• Investment in digital supply‑chain tracking to improve transparency

---

6️⃣ 5. LFB Group

Headquarters: Lyon, France
Key Offering: Bovine serum albumin and immunoglobulin products for biopharma and research

LFB’s strong presence in the European market is underpinned by rigorous quality certifications and a deep understanding of regulatory requirements. The firm’s expansion into regenerative‑medicine‑grade plasma fractions is a key growth lever.

Sustainability & Growth Initiatives:

• Adoption of renewable energy sources for processing facilities
• Development of pathogen‑reduced plasma to meet emerging safety standards
• Collaboration with biotech firms to co‑develop niche therapeutics

---

5️⃣ 6. Miltenyi Biotec

Headquarters: Bergisch‑Gladbach, Germany
Key Offering: Cell‑culture media and diagnostic reagents incorporating animal plasma components

Miltenyi Biotec’s portfolio is heavily oriented toward research and diagnostics, where high‑purity plasma fractions are essential. The company’s recent investment in automated fractionation platforms has improved yield and consistency.

Sustainability & Growth Initiatives:

• Implementation of closed‑loop water systems to reduce consumption
• Development of synthetic alternatives for low‑risk applications
• Strategic partnerships with academic labs for product validation

---

4️⃣ 7. Baxter International

Headquarters: Deerfield, USA
Key Offering: Plasma‑derived products for clinical and research use

Baxter’s broad distribution network and strong brand recognition in the medical device space give it a competitive edge in the plasma market. The firm’s focus on expanding its therapeutic portfolio aligns with the growing demand for biologics.

Sustainability & Growth Initiatives:

• Investment in energy‑efficient cryogenic storage solutions
• Collaboration with vaccine developers to secure supply contracts
• Expansion of R&D efforts into cell‑therapy‑grade plasma fractions

---

3️⃣ 8. Thermo Fisher Scientific

Headquarters: Waltham, USA
Key Offering: Laboratory reagents and cell‑culture media featuring animal plasma components

Thermo Fisher’s strong presence in the life‑science market positions it well to capture demand from research institutions. The company’s recent launch of a new line of ultra‑pure plasma fractions supports its commitment to high‑quality products.

Sustainability & Growth Initiatives:

• Adoption of digital supply‑chain tools for traceability
• Investment in renewable energy for production sites
• Collaboration with biotech firms for co‑development of next‑generation therapeutics

---

2️⃣ 9. Tiantan Biological

Headquarters: Tianjin, China
Key Offering: Bovine and porcine plasma for pharmaceutical and feed applications

Tiantan’s rapid expansion is driven by government support for domestic biopharmaceutical development. The firm’s focus on high‑yield processing technologies has positioned it as a key supplier in the Asia‑Pacific region.

Sustainability & Growth Initiatives:

• Implementation of blockchain traceability for raw material sourcing
• Investment in energy‑efficient cryogenic infrastructure
• Partnerships with regional slaughterhouses to secure disease‑free plasma

---

1️⃣ 10. Hualan Biological Engineering

Headquarters: Shanghai, China
Key Offering: Plasma‑derived proteins for vaccine and therapeutic development

Hualan’s focus on vaccine raw materials has earned it a prominent position in the rapidly growing Chinese biopharma market. The company’s recent investment in advanced pathogen‑inactivation technologies enhances product safety and regulatory compliance.

Sustainability & Growth Initiatives:

• Adoption of renewable energy sources for processing facilities
• Development of eco‑friendly cryopreservation protocols
• Collaboration with global biopharma firms for joint product development

---

Download FREE Sample Report: Frozen Animal Blood Plasma Market – View in Detailed Research Report

Get Full Report Here: Frozen Animal Blood Plasma Market – View in Detailed Research Report

Outlook: 2026‑2034 Market Projection

With the biopharmaceutical sector continuing to prioritize biologics, the frozen animal blood plasma market is set to evolve. The forecasted growth from 2026 to 2034 reflects a steady expansion driven by increased vaccine production, cell‑therapy applications, and high‑value feed supplements. Companies that invest in advanced cryogenic technology, supply‑chain resilience, and regulatory compliance are positioned to capture the majority of this growth.

Future Trends Shaping the Market

• Adoption of automated fractionation platforms to boost yield and reduce cost.
• Expansion of pathogen‑reduced plasma products to meet tightening safety standards.
• Integration of blockchain for end‑to‑end traceability across the supply chain.
• Growth of synthetic and cell‑cultured plasma alternatives as technology matures.
• Increasing focus on sustainability, with energy‑efficient cryogenic storage and waste‑reduction protocols.